Oxford Genetics signs major contract for CRISPR engineered mammalian cell lines

| By | Cellular Engineering, R&D
0
82

Oxford Genetics, a leader in innovative synthetic biology-based technologies for biologics discovery, development and delivery, has secured a multi-million pound contract with a leading multi-billion dollar global ecommerce provider of reagents and tools to the research and clinical community.

As part of the agreement, Oxford Genetics will leverage its high throughput automated genomic engineering platform for CRISPR modification of mammalian cell lines.

Headquartered in Oxford, UK, Oxford Genetics is a leading synthetic biology company dedicated to developing and delivering technologies and services to its customers that will help to change the gene editing industry.

The company’s use of automation allows it to develop new and innovative solutions, the latest of which is its mammalian CRISPR cell line engineering platform.

SOURCE: oxford genetics
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.